Solutionreach vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 74)
Solutionreach logo

Solutionreach

LeaderHealthtech

Patient Engagement Platform

Patient engagement and communication platform for dental, medical, and optical practices with 400+ PMS integrations. Lehi UT; founded 2000;

AI VisibilityBeta
Overall Score
B74
Category Rank
#87 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
70
Perplexity
77
Gemini
72

About

Solutionreach is a Lehi, Utah-based patient engagement platform that has served dental, medical, optometry, and specialty healthcare practices with automated appointment reminders, patient messaging, satisfaction surveys, and online review management since 2000. As one of the earliest companies to build technology specifically for healthcare practice patient communication, Solutionreach has established a large installed base across independent practices and group practices in the United States. The platform integrates with over 400 practice management and EHR systems, triggering automated patient communication workflows based on appointment data, recall schedules, and clinical events—without requiring manual staff intervention for each individual patient interaction.\n\nSolutionreach's patient retention capabilities are central to its value proposition for healthcare practices. Research consistently shows that automated recall outreach significantly increases the percentage of patients who return for follow-up care and preventive appointments, and Solutionreach's multi-channel recall sequences—combining text, email, and phone reminders sent at configurable intervals—help practices reduce the attrition that erodes practice revenue over time. The platform's satisfaction survey module automatically collects patient feedback after appointments and routes positive responses to review sites while flagging negative feedback for internal service recovery, helping practices manage their online reputation systematically.\n\nSolutionreach has expanded its platform with online scheduling, telehealth integration, and digital patient intake forms to address the growing patient expectation for digital access to healthcare services. The company also offers practice benchmarking through aggregated data insights that allow practices to compare their recall rates, no-show rates, and online review volumes against peers in their specialty and geography. Solutionreach competes with Weave, Lighthouse 360, and RevenueWell in the dental and multi-specialty patient engagement market, differentiating on its depth of EHR and PMS integrations and its long track record with independent practice customers.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

74
Overall Score
81
#87
Category Rank
#17
75
AI Consensus
71
stable
Trend
stable
70
ChatGPT
80
77
Perplexity
75
72
Gemini
77
78
Claude
86
69
Grok
85

Key Details

Category
Patient Engagement Platform
General
Tier
Leader
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Solutionreach
Patient Engagement Platform

Integrations

Both integrate with
Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.